Editas Medicine Inc EDIT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EDIT is a good fit for your portfolio.
News
-
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
-
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
-
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
-
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
-
Editas Medicine Announces First Quarter 2024 Results and Business Updates
-
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
-
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
-
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals — Update
Trading Information
- Previous Close Price
- $5.57
- Day Range
- $5.51–5.85
- 52-Week Range
- $4.45–11.69
- Bid/Ask
- $5.44 / $5.75
- Market Cap
- $464.64 Mil
- Volume/Avg
- 1.0 Mil / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 226
- Website
- https://www.editasmedicine.com
Comparables
Valuation
|
Metric
|
EDIT
|
NTLA
|
GBIO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.58 | 2.46 | 1.77 |
Price/Sales | 6.45 | 44.05 | 23.26 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EDIT
|
NTLA
|
GBIO
|
|---|---|---|---|
Quick Ratio | 4.46 | 8.45 | 7.75 |
Current Ratio | 4.60 | 9.03 | 8.01 |
Interest Coverage | — | — | — |
Quick Ratio
EDIT
NTLA
GBIO
Profitability
|
Metric
|
EDIT
|
NTLA
|
GBIO
|
|---|---|---|---|
Return on Assets (Normalized) | −29.23% | −26.32% | −23.97% |
Return on Equity (Normalized) | −41.61% | −31.79% | −40.92% |
Return on Invested Capital (Normalized) | −42.70% | −32.85% | −33.29% |
Return on Assets
EDIT
NTLA
GBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Fygdmztzn | Pqds | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nqmrphhp | Dhgsrr | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rnxblfnp | Gqrznl | $118.7 Bil | |||
| Moderna Inc
MRNA
| Rzljdvmr | Zmtzk | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ypqbczzg | Hpfflr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Gzkwlfx | Kvqb | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Xxmryfbf | Mrw | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vtwtjhvhx | Zspyy | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xptglvpc | Clg | $15.0 Bil | |||
| Incyte Corp
INCY
| Sdwjshjpv | Bjkdl | $13.5 Bil |